Prices are updated after-hours
Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Phase 2    crawled time : 13:04    save search
AnaptysBio Reports Imsidolimab POPLAR Phase 2 Clinical Trial in Moderate-to-Severe Palmoplantar Pustulosis (PPP) Did Not Meet Primary Endpoint
Published: 2021-03-08 (Crawled : 13:04) - globenewswire.com
ANAB | $18.865 -1.64% 65K twitter stocktwits trandingview |
Health Technology
 | | O: -37.22% H: 10.27% C: 5.46%
phase 2 trial
Gainers vs Losers
54% 46%

Top 10 Gainers
CSSE 4 | $0.3499 129.74% 150M twitter stocktwits trandingview |
Consumer Services
CZOO | $11.04 121.24% 9.6M twitter stocktwits trandingview |

BOF | $2.05 75.21% 78M twitter stocktwits trandingview |

AMST | $3.2 60.0% 63M twitter stocktwits trandingview |
Technology Services
LICN | $0.8592 53.43% 13M twitter stocktwits trandingview |

WIMI | $1.05 44.75% 13M twitter stocktwits trandingview |
Technology Services
TROO | $1.51 38.53% 5.6M twitter stocktwits trandingview |
Manufacturing
MULN | News | $3.675 34.62% 11M twitter stocktwits trandingview |
Information
RILY | $27.91 28.5% 8.9M twitter stocktwits trandingview |
Finance
WHLM | $6.43 26.58% 580K twitter stocktwits trandingview |
Commercial Services
Your saved searches
Save your searches and get alerts when important news are released.